EXTON, Pa., Dec. 13, 2010 /PRNewswire/ — BioTrends Research Group, Inc. finds that with the introduction of Novartis’ Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate major shifts in the landscape of the MS market. One month after the launch of Gilenya, trial and uptake of Extavia, a DMA launched by Novartis one year earlier, continues to be tempered due to the perception that Extavia is a “me too” agent -a perception made even more noticeable by the availability of the new and unique DMA, Gilenya. In fact, compared to previous waves, both current and anticipated patient share of Extavia have decreased due in part to a drop in the number of high prescribers of Extavia.
The recently released fourth and final wave of the LaunchTrends®: Extavia report series finds that the small amount of Extavia use is mostly driven by out-of-pocket cost concerns with other DMAs and that managed care reimbursement is playing less of a role compared to the role it played in the first year of Extavia’s commercial availability. In fact, perceptions of the managed care process for Extavia have declined since earlier waves. While Novartis detailing seems to be primarily focused on Gilenya, neurologists who were recently detailed on Extavia are more likely to have experience with the DMA. While anticipated prescribing of Gilenya is expected to rise substantially over the next six months, surveyed neurologists believe that any change in their prescribing of Extavia will be minimal.
****************************************************************
If you find our information valuable,
please donate by clicking here
****************************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews